Antibodies against polysaccharide type 3 and pneumococcal proteins demonstrate synergistic protective effect in a highly virulent type 3 invasive disease model in mice.

ABSTRACT: Streptococcus pneumoniae serotype-3 (ST-3) continues to be a major contributor to pneumococcal disease burden despite its inclusion in multivalent pneumococcal conjugate vaccines (PCV). Therefore, there is a pressing need to develop vaccines that can elicit more versatile immune responses against ST-3. To this purpose, our approach was to evaluate MAPS technology-based vaccine candidates in which biotinylated pneumococcal polysaccharides are non-covalently complexed with biotin-binding proteins. One such protein was SPP2, a fusion protein containing a nonhemolytic mutant of pneumolysin (Ply). The immunogenicity of SPP2 as a component of a vaccine candidate containing over 30 pneumococcal capsular polysaccharides, including ST-3 capsule (CPS3), was evaluated in rabbits. The vaccine d

SUBMITTER: Stevenson TC 

PROVIDER: S-EPMC12741848 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature